With this formal appointment, Dr. Cigdem Akman continues the exceptional leadership she has demonstrated over the past year in driving the overall expansion of the division’s clinical, research, and education programs.

The brain and spine tumor programs at NewYork-Presbyterian integrate multiple disciplines to provide comprehensive treatment strategies that include minimally invasive surgery, radiation therapies, and intra-arterial chemotherapy.

A family history of Alzheimer’s disease has been the driving force for a NewYork-Presbyterian/Weill Cornell physician on a mission to intervene before the disease takes hold.

Scott A. Small believes the key in leading scientists down a new pathway for drug discovery may be in targeting a biological mechanism in the cell called retromer endosomal dysfunction.

In October 2017, renowned neuro-oncologist Howard A. Fine, was awarded a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

At the Eleanor and Lou Gehrig ALS Center at NewYork-Presbyterian/Columbia, clinicians and scientists are leading efforts to combat amyotrophic lateral sclerosis and other motor neuron diseases.

A NewYork-Presbyterian/Weill Cornell neurosurgeon is redefining treatment of essential tremor, as the first in New York to offer high-intensity focused ultrasound to treat the brain disorder.

Over the past three decades, Dr. Manikkam Suthanthiran and his colleagues at NewYork-Presbyterian/Weill Cornell is responsible for much of the progress in kidney transplantation.